| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
SAN DIEGO, Oct. 14, 2019 /PRNewswire/ – Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, announced today that Ivor Royston, MD, President and...
PR Newswire, San Diego, August 1, 2019 – Viracta Therapeutics, Inc. announced today that it has appointed Dan Chevallard as Chief Financial Officer and Xiaohu Deng, Ph.D. as Senior Vice...
PR Newswire, San Diego, June 3, 2019 – Viracta Therapeutics, Inc. presented updated results today at the 2019 ASCO Annual Meeting from the Ph1b portion of the ongoing Phase 1b/2 clinical trial...
PR Newswire, San Diego, May 15, 2019 – – Viracta Therapeutics, Inc. announced today that it will present new clinical data during a poster session at the 2019 American Society of Clinical...
PR Newswire, San Diego, April 16, 2019 – Viracta Therapeutics, Inc. announced today that the U. S. Food & Drug Administration (FDA) has granted Orphan Drug Designations (ODD) to their Phase 2...
